ArticleThe American journal of pathology2009
The effect of plasma from muscle-specific tyrosine kinase myasthenia patients on regenerating endplates.
Article in The American journal of pathology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 40 citations in OpenAlex.
- Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology.Frontiers in immunology · 2020Review
- The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis.Journal of anatomy · 2014Review
- Autoantibodies to agrin in myasthenia gravis patients.PloS one · 2014Article
- Effects of the ß2-adrenoceptor agonist, albuterol, in a mouse model of anti-MuSK myasthenia gravis.PloS one · 2014Article
- Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis.The Journal of clinical investigation · 2013Article
- Autoantibodies to neurotransmitter receptors and ion channels: from neuromuscular to neuropsychiatric disorders.Frontiers in genetics · 2013Review
- Article
- Animal models of antimuscle-specific kinase myasthenia.Annals of the New York Academy of Sciences · 2012Article
- Muscle autoantibodies in myasthenia gravis: beyond diagnosis?Expert review of clinical immunology · 2012Review
- Acute severe animal model of anti-muscle-specific kinase myasthenia: combined postsynaptic and presynaptic changes.Archives of neurology · 2012Article
- Anti-MuSK autoantibodies block binding of collagen Q to MuSK.Neurology · 2011Article
- In response to "current approach to seronegative myasthenia" by Z. Argov.Journal of neurology · 2011Article
- Patient autoantibodies deplete postsynaptic muscle-specific kinase leading to disassembly of the ACh receptor scaffold and myasthenia gravis in mice.The Journal of physiology · 2010Article
- Plasma vitronectin is reduced in patients with myasthenia gravis: Diagnostic and pathophysiological potential.Journal of circulating biomarkersArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Muscle-specific tyrosine kinase (MuSK) is essential for clustering of acetylcholine receptors (AChRs) at embryogenesis and likely also important for maintaining synaptic structure in adult muscle. In 5 to 7% of myasthenia gravis (MG) cases, the patients' blood contains antibodies to MuSK. To investigate the effect of MuSK-MG antibody on synapse regeneration, notexin was used to induce damage to the flexor digitorum brevis muscle. We administered aliquots of MuSK-MG patients' plasma to the flexor digitorum brevis twice daily for a period up to 21 days, and muscles were investigated ex vivo in contraction experiments. AChR levels were measured with (125)I-alpha-bungarotoxin, and endplates were studied with quantitative immunohistochemistry. In normal muscles and in 14-day regenerated muscles, MuSK plasma caused impairment of nerve stimulus-induced contraction in the presence of 0.35 and 0.5 mmol/L Ca(2+) with or without 100 to 400 nmol/L tubocurarine. Endplate size was decreased in regenerated muscles relative to controls; however, we did not observe such differences in muscle not treated with notexin. MuSK plasma had no effect on the amount and turnover rate of AChRs. Our results suggest that anti-MuSK antibodies influence the activity of MuSK molecules without reducing their number, thereby diminishing the size of the endplate and affecting the functioning of AChRs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.